SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bolt Biotherapeutics, Inc.

NEW YORK, 24 June 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in Bolt Biotherapeutics, Inc. (“Bolt” or the “Company”) (NASDAQ: BOLT). Such investors are advised to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether Bolt and certain of his officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information on joining the class action lawsuit.)

At May 14, 2024Bolt announced in a press release that the company would “cease further development of trastuzumab imbotolimod (BDC-1001), Bolt’s key asset, and reduce its workforce by approximately 50%.” Following Bolt’s announcement, several analysts downgraded the company’s stock.

Following this news, Bolt’s share price fell 00,49 € per share or more than 37.12%, and closed at $00.83 per share on May 15, 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of victims of securities class action litigation. FraudBreach of fiduciary duty and corporate misconduct. The firm has won numerous millions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.